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Abstract Decision-making in the management of organ-confined prostate cancer is
complex as it is based on multi-factorial considerations. It is complicated by a
multitude of issues, which are related to the patient, treatment, disease, availability
of equipment(s), expertise, and physicians. Combination of all these factors play a
major role in the decision-making process and provide for an interactive decision-
making preferably in the multi-disciplinary team (MDT) meeting. MDT decisions
are comprehensive and are often based on all factors including patients’ biological
status, disease and its aggressiveness, and physician and centres’ expertise. However,
one important and often under rated factor is patient-related factors. There is con-
siderable evidence that patients and physicians have different goals for treatment
and physicians’ understanding of their own patients’ preferences is not accurate.
Several patient-related key factors have been identified such as age, religious beliefs,
sexual health, educational background, and cognitive impairment. We have focused
on these areas and highlight some key factors that need to be taken considered whilst
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counselling a patient and understanding his choice of treatment, which might not
always be match with the clinicians’ recommendation.
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Introduction
With 181 000 new cases diagnosed in 2016, prostate
cancer is the most frequently diagnosed cancer in men
in USA. However, there has been a small drop in the inci-
dence in the last few years. The drop in prostate cancer
incidence has been attributed to decreased PSA testing
from 2008 to 2013 in the wake of the USA Preventive Ser-
vices Task Force recommendations against routine use of
the test to screen for prostate cancer (Grade D) in those
aged 75 years in 2008 and in all men in 2011 because
of growing concerns about over diagnosis and over treat-
ment [1]. More than 80% of men diagnosed with prostate
cancer have clinically localised disease [2]. Patients with
localised disease can be treated by a variety of options
including radiotherapy (RT), surgery, or active surveil-
lance (AS). Decision concerning these options is often
based on physician’s preference or patient preference.
Either of these ways have inherent deficiencies.
The decision-making in localised prostate cancer is
complicated by variability in the biological potential
(clinical aggressiveness), age at diagnosis, comorbid con-
ditions, patients’ perception and life style, social set up
and available help at home, physicians’ preference (often
influenced by financial incentives, ego, enthusiasm for a
particular management option amongst other factors),
and not least of all the spectrum of management options
from AS to major surgery.
According to the National Comprehensive Cancer
Network (NCCN) guidelines 2018, organ-confined pros-
tate cancer can be classified into six different categories
and decision-making in general, and patient participa-
tion in particular, can vary according to different cate-
gories (Table 1).
Prostate cancer is a unique entity amongst urological
cancers. Not only because of its importance as the most
common cancer in males [3], but also due to the variety
of available treatment modalities, which include:
watchful waiting, AS, radical prostatectomy (RP; open
or minimally invasive), external beam radiotherapy
(EBRT), brachytherapy, cryotherapy, and high-
intensity focused ultrasound, as well as palliative hor-
monal and medical therapy [4]. In the decision-making
process, meticulous assessment of the patient diagnosed
with prostate cancer is of utmost importance. An accu-
rate medical history should include current symptoms,
such as bone pain for example could hint towards bone
metastases, making a curative approach impossible. A
history of previous abdominal operations might make
laparoscopic/robot-assisted surgery difficult, and history
of medical illness e.g. severe cardiac or respiratory
illness would compromise fitness for surgery overall
and possibly make active treatment in general inade-
quate. In addition, a complete physical examination is
essential to assess fitness for surgery and a DRE to
assess the local disease and the pelvic floor muscle.
Investigations such as TRUS, CT, MRI and bone scan
for selected cases are tools for proper assessment before
presenting the case to the multi-disciplinary team
(MDT). The information so gained needs to be consid-
ered whilst evaluating the variety of treatment options
in view with the constantly changing guidelines and
evidence-based changes in prostate cancer treatment.
Consequently, the role of a multi-disciplinary approach
to find the most suitable treatment in each individual
case cannot be underestimated [5]. However, these scien-
tific aspects are not the only key factors in decision-
making, as the patients choice is majorly influenced by
factors such as age, religious beliefs, sexual health, edu-
cational background, and cognitive state. This can be
demonstrated in patients, who are in the same risk
group, yet they decide on different treatment modalities.
Studies have shown that surgeon characteristics are
associated with patients’ treatment strategy after con-
trolling for patient and tumour characteristics. The var-
ious surgeon factors include: gender, academic/private
training, and type of medical degree. However, further
work is needed to confirm the associations to determine
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whether they reflect surgeon behaviour, patient
response, or physician–patient interactions [6].
Treatment options for localised prostate cancer
Patients with organ-confined prostate cancer have sev-
eral potentially curative options to choose from includ-
ing RP, EBRT, and brachytherapy [4,7,8].
There is no consensus for the optimal treatment strat-
egy for organ-confined prostate cancer and current guide-
lines do not indicate the best choice of therapy with
regards to oncological and survival outcome. The active
treatment options (surgery, RT, hormonal therapy) all
have a potential to significantly impact quality of life
(QoL). This includes impaired urinary, sexual or bowel
functions besides an association with psychological dis-
tress such as uncertainty and social (relationship) prob-
lems [9,10]. The efficacy and complications vary widely
even within one treatment modality making decision-
making complex [11]. In the literature it is evident that
side-effect profiles differ between the treatment modali-
ties analysed; men after RP more commonly report uri-
nary and sexual side-effects vs bowel symptoms
following RT. In a recent report, notable findings from
the analysis of emotions expressed, indicates that age
has an important bearing. Patients with prostate cancer
aged < 40 years expressed significantly high positive
and negative emotions compared with other age groups.
Partners of patients expressed more negative emotions
than the patient himself [12]. In a recent French study,
the authors noted that the main reasons for decisional
regret were the fact that patients received incomplete
information about prostate cancer (40%) and the impact
of treatment on continence (34%). The information on
the oncological outcome was considered adequate by
32.3% of the satisfied group and 14.3% of the
decisional-regret group (P= 0.003), and with regard to
urinary incontinence the information received was con-
sidered complete in 41.4% and 17.4%, respectively
(P< 0.01) [13].
Table1 Prostate cancer risk stratification therapy options.
Risk group Clinical/pathological features Initial therapy
Very-low-risk group T1c AND
Gleason score  6/ Grade Group 1 AND
PSA level < 10 ng/mL AND
<3 prostate biopsy/cores positive, 50 cancer in
each fragment/core AND
PSA density < 0.15 ng/mL/mL
Expected patient survival  20 years:
AS
EBRT or brachytherapy
RP ± pelvic lymph node dissection (PLND)
Expected patient survival 10–20 years:
AS
Expected patient survival < 10 years:
Observation
Low-risk group T1–T2a AND
Gleason score  6/Grade Group 1 AND
PSA level < 10 ng/mL
Expected patient survival  10 years:
AS
EBRT or brachytherapy
RP ± PLND
Expected patient survival < 10 years:
Observation
Favourable-intermediate-risk
group
T2b–T2c OR
Gleason score 3 + 4 = 7/Grade Group 2 OR
PSA level 10–20 ng/mL AND
% positive cores < 50%
Expected patient survival  10 years:
AS
EBRT or brachytherapy alone
RP ± PLND
Expected patient survival < 10 years:
EBRT or brachytherapy alone
Observation
Unfavourable-intermediate-risk
group
T2b–T2c OR
Gleason score 3 + 4 = 7/Grade Group 2 or
Gleason score 4 + 3 = 7/Grade Group 3 OR
PSA level 10–20 ng/mL
Expected patient survival  10 years:
RP ± PLND
EBRT+ ADT OR
EBRT+ brachytherapy ± ADT
Patient expected survival < 10 years:
EBRT+ ADT OR
EBRT+ brachytherapy ± ADT
Observation
High-risk group T3a OR
Gleason score 8/Grade Group 4 or Gleason score
4 + 5 = 9/Grade Group 5 OR
PSA level > 20 ng/mL
Patient expected survival > 5 years:
EBRT+ ADT OR
EBRT+ brachytherapy + ADT
RP+ PLND
Very-high-risk group T3b–T4 OR
Primary Gleason pattern 5 OR
>4 cores with Gleason score 8–10/ Grade Group
4 or 5
As for high-risk category
PLND, pelvic lymph node dissection.
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The NCCN and AUA have recommended AS for
selected patients in whom treatment is considered safe
to defer with the intention of avoiding over treatment
of low-risk disease [5,6]. However, these patients live
with a constant fear and stress of disease progression
[14].
To improve the efficacy–morbidity profile, minimally
invasive treatment options, such as laparoscopic and
robot-assisted RP, have evolved; similarly RT has also
modified to deliver higher doses of radiation to more
tightly defined anatomical regions. Three-dimensional
conformal and intensity-modulated RT with or without
androgen-deprivation therapy (ADT), low- and high-
dose-rate brachytherapy and stereotactic radio-surgery
helps this [15].
Patients who are old and have significant medical
comorbid conditions are less fit surgical candidates
and benefit from RT. In a population-based cohort
study, Daskivich et al. [16] analysed the data of patients
with prostate cancer from the Surveillance, Epidemiol-
ogy and End Results (SEER) and found that older
men diagnosed with prostate cancer are at risk of both
over and under treatment of their cancer and appropri-
ate management in these less fit patients can be challeng-
ing as co-existing medical conditions can impact
treatment tolerance and the likelihood of benefitting
from aggressive treatment.
Lunardi et al. [17] analysed a population-based can-
cer registry for the impact of age and comorbidity on
prostate cancer treatment choices and on multivariate
analysis showed that the chosen definitive treatment
for localised prostate cancer was influenced by age and
comorbidities. There was a significant reduction in RP
practice compared to EBRT in order to avoid the surgi-
cal complications in unfit patients.
Decision-making process in organ-confined (localised)
prostate cancer
Informed decision-making based on patient preferences
is a key component to ensure effective, patient-centred
care [18]. Decision-making is complex and difficult in
patients with organ-confined prostate cancer. This is
due not only to the variable biological potential of the
cancer but also due to patients’ factors such as life
expectancy and medical comorbid conditions [4,5], as
treatment can have a significant impact on patient’s
QoL and length of life [9].
The information needs of patients with localised
prostate cancer are enormous and there is evidence that
their needs are not being met through usual care [19]. It
is also important to understand how and why patients
make their treatment decisions and the effect that these
treatment choices have on long-term outcomes [13].
Over treatment of low-risk cancers remains a concern.
Various clinical parameters such as age, PSA level at
diagnosis, cores involved, and PSA density, are cur-
rently utilised predictors. More recently, the Prostate
Health Index (PHI), the 4 Kallikrein (4K) score, and
patient-related factors (e.g. age, race, and family his-
tory) have been assessed for applicability to differentiate
indolent from aggressive prostate cancers. The life
expectancy is a commonly used metric to decide between
treatment options. Age, comorbidities (as objective
assessed by Charlson Comorbidity Index, CCI) are used
to determine life expectancy. Boehm et al. [20] recently
reported that in patients with non-metastatic prostate
cancer, neither age nor CCI can accurately estimate
overall mortality or life expectancy in excess of 10 years.
All guidelines consider life expectancy as an important
determinant for devising a management strategy; it is
not easy to identify tools that could be appropriately
used into a point-of-care decision aid [21].
The biological potential of prostate cancer is variable,
nearly one-third have low-risk tumours that are not
lethal and remain asymptomatic during their lifetime.
Currently, various nomograms are in use to predict pos-
itive surgical margins, particularly extracapsular exten-
sion (ECE). ECE has a significant impact on the
management strategy and patient prognosis. Identifica-
tion of ECE before surgery is therefore pivotal in clinical
decision-making. It not only influences surgical
decision-making, but also if nerve sparing will be per-
formed. Sacrificing the neurovascular bundle negatively
impacts QoL by increasing the chances and recovery
period of both continence [22] and potency [23]. Cur-
rently, available models and nomograms are based on
clinical staging based on ultrasonography, which signif-
icantly under stages ECE in over one-quarter of patients
[24]. Recently, multiparametric MRI (mpMRI)-based
staging has been proposed to minimise understaging
[17]. It has been noted that mpMRI improved accuracy
of existing clinical nomograms for prediction of patho-
logical ECE [25]. With the introduction of mpMRI dur-
ing the last decade, significant advances have been made
in prostate cancer pre-therapy staging, with consequent
risk stratification and hence its integration into clinical
decision-making with the goal of preventing over treat-
ment of low-risk disease and selection of optimal aggres-
sive treatment in high-risk disease [26]. mpMRI also
provides the highest clinical value when used as part
of a multi-disciplinary collaboration between the treat-
ing physician and interpreting radiologist.
Biological markers [urine prostate cancer antigen 3
(PCA3), transmembrane protease serine 2:v ets ery-
throblastosis virus E26 oncogene homolog (TMPRSS2-
ERG) gene fusion, or PSA isoforms] are promising;
along with genomics on the tissue sample itself. How-
ever, further data are needed in order to use these mark-
ers in standard clinical practice [27]. In the recent years,
significant progress has been made in the mutational
landscape in the development and progression of
370 Nazim et al.
prostate cancer. This has opened new avenues for devel-
opment of molecular markers in predicting prognosis,
diagnosis, and monitoring drug response. However, cur-
rently their clinical applicability is limited due to a lack of
clinical validation, limitations, and cost [28].
Physicians’ bias and perceptions about treatment decision-
making in prostate cancer
Evidence suggests that patients and physicians have dif-
ferent goals for treatment and physicians’ understand-
ings of their own patients’ preferences are not accurate
[29].
Treatment decision is highly variable and is influ-
enced by non-clinical factors, such as patient’s demo-
graphics, geography and physicians’ own specialty
(urologist, radiation oncologists) [30], as they would
intentionally or unintentionally reveal their treatment
preferences at the time of diagnosis.
A recently published study identified physicians’
(including urologists, radiation oncologists and primary
care physicians) perceptions of patients’ considerations,
which are important for decision-making in prostate
cancer [31]. Physician recommended AS for patients’
with characteristics, such as older age, fear of treatment
side-effects, comorbidities, life expectancy, anxiety, and
willingness and ability to follow a surveillance protocol.
Physicians also reported that their decision and recom-
mendation were also influenced by patients’ anxiety
about cancer and the healthcare setting of physicians
with recommendation of active treatment in fee-for-
service settings (financial incentive) compared to inte-
grated healthcare settings [16].
Various factors also contribute towards shared
decision-making in prostate cancer. These include not
only patient demographics such as age, comorbidity
and performance status, but also their life expectancy
and family history of longevity. Various guidelines rec-
ommend use of population-based scales such as mortal-
ity tables to estimate life expectancy, as only
chronological age should not be considered as the main
decision factor. Nomograms and tools are devised to
define the optimal treatment options for patients diag-
nosed with cancer after weighing the individual’s risk
of disease progression against risk of non-cancer death
[32].
Patients’ bias and preferences for treatment selection and
subsequent decision regret
Studies have shown that patients with prostate cancer
do not receive the necessary information needed for
understanding of the disease and treatment options,
with fear and misconceptions prevailing in their minds.
They therefore rely on the treatment decision of their
physicians, family, anecdotes, and opinions of others
[33]. Patients often report high levels of decision-
related stress both at the time of diagnosis and at the
completion of treatment [7].
Patients’ experiences differ markedly between and
within the treatment options, and they sometimes expe-
rience regret about not only the choice they made but
also the way the decision was made regarding a particu-
lar treatment option [9]. Up to a quarter of patients
report regrets about their treatment decision, this is
more prevalent amongst men who assume a more pas-
sive role during decision-making [7].
A systematic review of regret following treatment of
localised prostate cancer identified that treatment-
related toxicity especially urinary, sexual and bowel
dysfunction were the most common factors for regret
followed by old age and longer time since treatment.
A higher level of regret was found after RP than after
ERBT or brachytherapy [9].
Patients who undergo RT could experience signifi-
cant side-effects including urinary incontinence, gas-
trointestinal side-effects, erectile dysfunction, and
serious sequelae requiring urological procedures and
hospital admissions which could impact QoL and be
associated with significant regret. RT is associated with
even serious side-effects such as formation of urinary fis-
tula and development of secondary malignancy. These
complications vary according to the institution, RT
dose, and technique of RT [34].
Patient-centred approach with consideration of values,
preferences and perceptions
To facilitate a decision, physicians need to tailor inter-
vention according to patients’ age and cancer aggres-
siveness and should develop strategies to reduce
patient’s concerns and misconceptions. Patients should
also be given sufficient time to consider treatment
options, which helps them to balance the information,
received from various sources [35]. Patients should be
given choices of treatment options with a detailed dis-
cussion on potential advantages and disadvantages that
they must consider based on their lifestyle, values, and
preferences. Treatment should be selected based on
patients own perceptions of risks and benefits rather
than selected from a predominantly medical perspective
[13].
Patient-related factors for decision-making in the
management of organ-confined prostate cancer
Age
The risk of developing prostate cancer increases with
age, but it can occur in a wide spectrum of age groups.
Age is also an important prognostic factor in treating
prostate cancer. Within the younger age group
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(the working labour group) the socioeconomic concerns
need to be considered, e.g. the patients employment
status. In this regard it has been shown that the younger
patient is more likely to opt for a surgical treatment,
whereas the older patient tends to receive a non-
surgical treatment [36], although this has slightly
changed after remarkable improvement in outcomes
following laparoscopic and robotic surgery. Younger
patients were also found to be more willing to be
involved in the decision-making process and more hope-
ful, whereas older patients were found to be avoiding
being involved and were found to be less participatory
in the decision-making process [37].
Religious beliefs
Amongst urological surgeons there is a tendency
towards seeing robotic RP a ‘gold standard’ for treat-
ment of organ-confined prostate cancer [38]. However,
every once in a while we face the situation that a patient
refuses surgical or even all treatment due to religious
beliefs. The classical example of Jehovah’s witnesses,
despite being rare, should be kept in mind, as this will
leave the decision maker no option for a curative treat-
ment but RT. In scenarios where RT is contraindicated
(e.g. previous pelvic irradiation or inflammatory bowel
diseases) the options left would be hormonal therapy
and watchful waiting or embarking on a high-risk sur-
gery. However, there seems to be some kind of flexibility
amongst Jehovah’s witnesses emerging in the past few
years, especially if the patient is well-informed about
the surgical option and the risk of blood transfusion.
There are even reports that a few patients have even
accepted blood transfusions if inevitable [39]. Indeed,
these patients accept surgery with allogenic blood
transfusion. Fregonesi et al. [40] reported use of
transfusion-free radical robotic surgery in this group.
As RP is historically associated with the potential for
significant blood loss, patients who refuse allogeneic
blood transfusion such as Jehovah’s Witnesses can be
challenging surgical candidates. Various strategies are
described in the literature to prevent or reduce the need
for blood transfusion, such as preoperative haemoglobin
boost utilising erythropoietin, normovolemic haemodi-
lution, and intraoperative cell salvage [41].
Sexual health
Since the concept of focusing on QoL rather than purely
on survival for patients with cancer was introduced to
modern cancer therapy, much has changed in decision-
making. It has been shown that patients may prefer
and appreciate a better QoL, even at the cost of poorer
survival rates [42].
In this respect maintenance of a healthy sexual life
after radical treatment is an increasing concern for
patients. Nowadays, it is not uncommon to be asked
directly by the patient about the possibility of a nerve-
sparing surgery or to see patients concerned about
penile shortening after RP. Changes in sexual function
should therefore routinely be discussed during patient
counselling. Since all radical treatment options have
an impact on sexual health, AS and focal therapies have
become the methods of choice for some patients.
In our practice the assessment of sexual health is now
a standard preoperative measure. A widely accepted
method for this assessment is through International
Index of Erectile Function score. The patient is also
thoroughly educated about the treatment options for
erectile dysfunction postoperatively. These include
phosphodiesterase type-5 inhibitors, intracavernosal
injections, vacuum erectile devices, and medicated ure-
thral systems. Use of penile prosthesis is the last line
of therapy for erectile dysfunction following radical
prostate surgery. In a recent study, Pillay et al. [43]
assessed QoL, psychological functioning, and treatment
satisfaction of men who underwent penile implantation
after RP. They noted that patients reported good sexual
function and treatment satisfaction.
Educational background
Understanding the details of the different prostate can-
cer treatment modalities and their potential complica-
tions requires a certain level of educational and
cultural background. Not only should the patient under-
stand the potential complications after surgery
(e.g. incontinence, erectile dysfunction) but should also
have sufficient educational background to understand
the principles of pelvic floor training for example or
penile rehabilitation. This educational background
may be the key factor that drives a patient to undertake
a prostate-screening test for example [44], as the benefit
of having a national prostate cancer screening pro-
gramme remains controversial. Patients with a family
history of prostate cancer are by far better informed
and it is easier to educate them about treatment modal-
ities. Nevertheless, regardless of the patients educational
background, every effort should be made by the medical
team to achieve an adequate understanding of all infor-
mation given, as studies show that many patients fail to
make the best decision because they were affected by the
experience of others and gathered information from
unreliable sources [45,46].
Online risk-prediction resources for prostate cancer
are now easily accessible and widely used by patients
for informed decision-making concerning screening
and diagnosis. Often these tools are not regularly
updated to incorporate newer biomarkers, imaging
studies etc. Of the many prediction tools, nomograms
provide superior, individualised, disease-related risk
estimations that facilitate management-related
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decisions. Nevertheless, many more predictive tools,
comparisons between them, and improvements to exist-
ing tools are needed [47].
There are many web-based patient-education materi-
als, we often refer to the one provided by the European
Association of Urology (EAU). Compared to conven-
tional educational tools such as booklets, online
web-based resources provide more prospects to tailor
information to patient’s individual needs [48].
Cognitive impairment
To achieve best possible treatment outcome an assess-
ment of psychological status is mandatory. Together
with educating the patient about his disease, qualified
psycho-oncological counselling should be initiated to
reveal any cognitive impairment, e.g., as this is associ-
ated with increased mortality [49]. Emotional state and
secondary depression were shown to improve in elderly
patients after surgical treatment but a pre-existing
cognitive impairment would not change, hence the
importance of the initial assessment. Many methods
for assessment are available. The most widely accepted
method to date is the mini-COG [50,51]. The Interna-
tional Society of Geriatric Oncology recommends per-
forming a comprehensive geriatric assessment in
elderly population including identifying comorbidities,
functional status (dependent or independent perfor-
mance), nutritional status and overall QoL [50].
AS/watchful waiting are the chosen options for elderly
patients with dementia and limited life-expectancy.
Various factors also need to be considered when choos-
ing curative treatment options, such as patient’s support
and independent performance.
Brachytherapy (if not contraindicated by a much
enlarged prostate or history of urinary retention) can also
be a safe option with good patient tolerance and minimal
gastrointestinal or genitourinary functional disturbance.
Data on ADT resulting in cognitive impairment are
conflicting. However, a discussion on the negative
impact on cognitive function of ADT should be part
of patient counselling prior to the start of treatment.
Due consideration should be given to explaining the
pros and cons in the light of comorbid conditions, life-
expectancy, and disease risk. There is dearth of data
on counselling patients about treatment options in
patients who have pre-existing dementia. It is clear that
a truly informed consent cannot be obtained under such
situations [52] and further aggravation of cognitive
dysfunction is expected.
Decision-making framework
Patients’ participation in decision-making for medical
care ranges within three categories of framework
according to a Control Preference Scale (CPS) describe
by Degner et al. [53]:
1. Active (patient’s autonomy): patient makes treatment deci-
sion alone.
2. Collaborative (shared decision-making): patient and physi-
cian make the treatment decision together and share the
responsibility
3. Passive (medical paternalism): Physician makes treatment
decision for patients [30]. Medical paternalism is based on
the belief that physicians know more than patients about
what is good for them [30] and therefore endorses physi-
cian’s authority. However, physicians who make decisions
on behalf of patients are often poor judges of patients’ val-
ues, preferences, QoL and life expectancy [54]. Shared
decision-making ensures better quality of care and increased
satisfaction for both the patients and medical staff [7].
Shared care/shared decision-making
This concept comprises an intentional and co-operative
communication between the patient and a clinician with
the aim of delivering high-value, patient-centred care [55].
Due to the complexity of prostate cancer diagnosis,
risk stratification, and the multitude of available treat-
ment options, patients themselves are not in a position
to take responsibility for treatment [12]. Shared
decision-making ensures that healthcare decision combi-
nes physician’s knowledge and expertise about a treat-
ment option with each individual patient’s preferences,
values, and life priorities [32], thus reducing decisional
conflicts [56]. The AUA guidelines encourage both urol-
ogists and patients to participate in shared decision-
making for prostate cancer [6].
A recently published randomised controlled trial
(RCT) ‘Procare’ criticised the current model follow-up
strategy for men with low- to intermediate-risk prostate
cancer [57]. It randomised patient’s care into shared care
vs usual care. Patients with usual care described more
distress and ongoing side-effects including psychological
issues compared to shared care. A study by Davison et al.
[58] showed that men who prefer a more collaborative
role are aware of more information about prostate can-
cer and test results, treatment options, and their impact
on QoL. Patients with newly diagnosed localised pros-
tate cancer and low health literacy levels were more vul-
nerable to mental distress than those with a high health
literacy level [59]. To promote shared decision-making,
online health information like e-health programmes
can provide patients and their families’ opportunity to
improve their health education and knowledge.
Decision aids
Background
Decision aids are particularly useful when there is no
consensus about best practice/‘gold standard’ for a par-
ticular condition (like organ-confined prostate cancer)
and judgments about treatment risk and benefits are
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more or less subjective [33]. Decision aids are tools
designed to improve shared decision-making and to
complement counselling from healthcare professionals
[33].
They facilitate patient participation and support
them making specific and deliberative choices amongst
treatment options and risk perceptions by reducing
decisional conflict through evidence-based description
of benefits and risks of different treatment options [60].
Content and types of decision aids
These aids contain numeric and graphic information to
describe possible outcomes of each option, helping
patients to reach a decision based on their own values
and preferences [37].
These aids convey balanced information about
different treatment options in their understandable
language and encourage them to pursue treatment
options appropriate to their situation. They are there-
fore different from conventional educational materials
and should be implemented in daily clinical care of
patients [37]. Decision aids use various media to convey
information and include personal interviews, written
and printed materials, audio recordings, videos and
multimedia presentations, and interactive computer-
based tools [61].
Rationale for decision aids
A Cochrane review studied 115 decision aids to assess
those used in RCTs and concluded that compared to
usual care, patients who used decision aids have greater
knowledge of treatment options, better understanding of
treatment risks, and their decisions were consistent with
individual values and preferences [33].
A systematic review showed that for localised pros-
tate cancer the use of decision aids is feasible and accept-
able, and have been shown to improve care in key
domains of decision-making, i.e. active participation,
gain in patients’ knowledge, alleviation of anxiety, and
improved satisfaction with the decision [62].
Adsul et al. [63] in a systematic review of decision aids
studied their role for helping make specific choices
amongst the options and outcomes relevant to health
status specific to prostate cancer treatment.
Role of multidisciplinary care and clinics
Dimensions needed for multidisciplinary care and shared
decision-making in patients with prostate cancer
Different dimensions such as content to be discussed
(type, detail of information), a facilitative environment,
and emotional support are important for the multidis-
ciplinary clinic when involved in shared decision-
making.
Multidisciplinary clinics
Multidisciplinary clinics are an effective tool to facilitate
the decision-making process. Contrary to consultation
with individual practitioners, the treatment patterns of
patients who attend multidisciplinary clinics are differ-
ent [64]. In MDT clinics, patient (with family members)
are informed about the full overview of the possible
treatment options available, along with the alternatives
at a particular setup after complete review of imaging
and pathology reports (staging). The patient’s risk pro-
file is determined to help them to choose the best possi-
ble option whilst maintaining QoL and a structured
follow-up care plan is given. A discussion of potential
risks and benefits of each treatment is made [65]. Studies
have shown that this real-time collaboration between
urologists, radiation oncologists, medical oncologists,
pathologists and radiologists helps in the adherence to
clinical guidelines and hence improved quality of care.
This also results in high satisfaction rate as appreciated
by the patient and their families [58].
A scheduled appointment in a multidisciplinary clinic
is often difficult, as coordination between specialties is
required [66]. Often the experts involved are working
in other hospitals and even across continents and this
introduces further complexity [67].
A multidisciplinary approach includes a thorough
assessment about patient characteristics such as poten-
tial longevity, medical and psychological concerns, and
patient’s tumour characteristics. Patients are educated
about their cancer and management choices by the urol-
ogists, radiation oncologists and other healthcare pro-
fessionals, and then the team makes a joint
recommendation about the treatment options [41].
These clinics help in appropriate communication with
patients about treatment options and prevent any omis-
sion of information availability, thus improving their
knowledge, fostering active participation in decision-
making, and reducing the level of anxiety and distress
[68]. Through the multidisciplinary and a patient-
inclusive approach an appropriate (shared) decision
can be made.
Conclusions
Decision-making in localised prostate cancer is difficult
as there is no ‘gold standard’ treatment. Often the con-
dition is asymptomatic and the patient is subjectively
worse after treatment. This results in an unhappy
patient, unless he is actively involved in the decision-
making process. There are forums like MDT, decision
aids etc. to facilitate this process. There are many
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personal factors such as age, religion, education, sexual
activity and psychological status, which can have a
major impact on the decision-making process and
should be considered whilst trying to counsel the patient
about the best treatment option. After all, the patient is
the only decision maker, we just provide him with the
choices.
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